Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22419059 | 0.92 | DDR1 (0.33) | DDR1 | |
| SCHEMBL22280382 | 0.90 | SMN1; SMN2 (0.37) | SMN1; SMN2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL20468526 | 0.86 | ALDH1A1 (0.32) | SMN1; SMN2KDM4EALDH1A1HPGDDDR1 | |
| SCHEMBL20455821 | 0.85 | DDR1 (0.35) | DDR1EIF4EBP1 | |
| SCHEMBL29521486 | 0.85 | DDR1 (0.35) | DDR1EIF4EBP1 | |
| SCHEMBL22280576 | 0.85 | DDR1 (0.33) | DDR1 | |
| SCHEMBL18506244 | 0.83 | SMN1; SMN2 (0.35) | SMN1; SMN2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL31141512 | 0.83 | SMN1; SMN2 (0.35) | SMN1; SMN2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL20465925 | 0.83 | SMN1; SMN2 (0.33) | SMN1; SMN2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL18357558 | 0.83 | DDR1 (0.34) | SMN1; SMN2KDM4EALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110248941-B | Aryl-or heteroaryl-substituted imidazopyridine derivatives and their use as pesticides | 拜耳公司 | 2022-09-06 | — | — | CN | disclosed |
| US-10772332-B2 | 2-(het)aryl-substituted fused heterocycle derivatives as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-15 | — | — | US | disclosed |
| US-10772332-B2 | 2-(het)aryl-substituted fused heterocycle derivatives as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-15 | — | — | US | disclosed |
| US-20200236940-A1 | 2-(HET)ARYL-SUBSTITUTED FUSED HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-07-30 | — | — | US | disclosed |
| US-20200236940-A1 | 2-(HET)ARYL-SUBSTITUTED FUSED HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-07-30 | — | — | US | disclosed |
| WO-2018141954-A1 | ARYL OR HETEROARYL-SUBSTITUTED IMIDAZO PYRIDINE DERIVATIVES AND THEIR USE AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018141954-A1 | ARYL OR HETEROARYL-SUBSTITUTED IMIDAZO PYRIDINE DERIVATIVES AND THEIR USE AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772332-B2 | 2-(het)aryl-substituted fused heterocycle derivatives as pesticides | CYP4X1, CYP1A1, CYP1A2 | SMN1; SMN2 2172/4885KDM4E 2601/4885ALDH1A1 591/4885 |
| US-20200236940-A1 | 2-(HET)ARYL-SUBSTITUTED FUSED HETEROCYCLE DERIVATIVES AS PESTICIDES | CYP4X1, CYP1A1, CYP1A2 | SMN1; SMN2 2172/4885KDM4E 2601/4885ALDH1A1 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.